Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Dronedarone for atrial fibrillation: a new therapeutic agent Patel PD; Bhuriya R; Patel DD; Arora BL; Singh PP; Arora RRVasc Health Risk Manag 2009[]; 5 (ä): 635-42Atrial fibrillation is the most common of the serious cardiac rhythm disturbances and is responsible for substantial morbidity and mortality. Amiodarone is currently one of the most widely used and most effective antiarrhythmic agents for atrial fibrillation. But during chronic usage amiodarone can cause some serious extra cardiac adverse effects, including effects on the thyroid. Dronedarone is a newer therapeutic agent with a structural resemblance to amiodarone, with two molecular changes, and with a better side effect profile. Dronedarone is a multichannel blocker and, like amiodarone, possesses both a rhythm and a rate control property in atrial fibrillation. The US Food and Drug Administration approved dronedarone for atrial fibrillation on July 2, 2009. In this review, we discuss the role of dronedarone in atrial fibrillation.|Amiodarone/adverse effects/*analogs & derivatives/therapeutic use[MESH]|Animals[MESH]|Anti-Arrhythmia Agents/adverse effects/*therapeutic use[MESH]|Atrial Fibrillation/*drug therapy/physiopathology[MESH]|Dronedarone[MESH]|Evidence-Based Medicine[MESH]|Heart Rate/*drug effects[MESH]|Humans[MESH]|Randomized Controlled Trials as Topic[MESH]|Treatment Outcome[MESH] |
